Project Grant R44HL139161

The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), awarded a $1,358,179 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Revidia Therapeutics, Inc. The award supports the completion of IND-enabling safety and toxicity testing for a subcutaneous formulation of the PTP1B inhibitor MSI-1436, a novel therapeutic approach for treating fatal cardiomyopathy in Duchenne muscular dystrophy patients. Key activities...

This $1,488,899 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the advanced development and validation of two innovative therapeutic compounds, YT-002 and YT-004, targeting specific protein kinases to preserve myocardial tissue and function following myocardial infarction. The research aims to optimize drug formulations, conduct comprehensive pharmacokinetic and pharmacodynamic studies,...

The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of South Florida a $517,475 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to develop novel small molecule compounds that activate NAD+ as a potential treatment for heart failure. The research aims to utilize medicinal chemistry, structure-activity relationship (SAR) modeling, and in vitro/ex vivo/in vivo screening to identify 1-2 lead P7C3-based small molecule candidates that can enhance...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $697,952 to the Beckman Research Institute of the City of Hope to investigate the mechanism and potential therapeutic targets for cardiac dysfunction caused by the tyrosine kinase inhibitor drug osimertinib. The research aims to: 1) Examine the role of the enzyme myosin light chain kinase 3 (MYLK3) in osimertinib-induced...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $259,464 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Leland Stanford Junior University. The purpose of this award is to study the potential benefits of combining mitochondria-rich extracellular vesicles (M-EVs) with guideline-directed medical therapy (GDMT) to improve cardiac function and viability in heart failure patients. The project will first determine the protective mechanisms of M-EVs...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $777,258 to the Beth Israel Deaconess Medical Center, Inc. (Bidmc) to conduct research aimed at improving the understanding and treatment of heart failure in patients with hypertrophic cardiomyopathy (HCM). The key objectives of this research project are to use advanced cardiac imaging techniques, such as cardiac magnetic resonance...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $784,206 to investigate the role of the CSF-1/CSF-1R axis in myocardial infarction (MI) repair and remodeling. The research team at Albert Einstein College of Medicine will examine the effects of macrophage-specific CSF-1R activation and fibroblast-derived CSF-1 on infarct healing, as well as the therapeutic potential of early...

This $156,600 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research program) supports research conducted by Dr. Glynnis Garry at the University of Texas Southwestern Medical Center. The goal is to characterize the role of the protein PHF7 in mediating cardiac reprogramming, which has the potential to promote heart regeneration following myocardial infarction. The award will fund studies to: 1) define PHF7's function in adult human...

The National Heart, Lung, and Blood Institute (NHLBI) awarded Novomedix LLC a $1,000,000 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct definitive (GLP) toxicity and toxicology studies for a novel small molecule that aims to protect against cardiotoxicity in triple negative breast cancer patients receiving anthracycline chemotherapy. The key products and services to be delivered through this award include: Developing and validating methods for analyzing...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, aims to develop biomimetic nanomaterials to modulate the immune response in the heart and spleen following a myocardial infarction. The $741,890 award to the Medical University of South Carolina will fund research to uncover the mechanisms by which spleen-targeted delivery of histone deacetylase (HDAC) inhibitors can produce therapeutic...